Following yesterday's rally in cannabis stock's driven by Aphria's (APHA) earnings, BofA Merrill Lynch analyst Christopher Carey said he doesn't see a case for sustainable upside yet until consensus estimates are cut further, which he thinks will ensue with the calendar Q3 results from the group. The reason that industry sales could be flat to down quarter-over-quarter sector-wide is that the cannabis industry is going from a period of inventory build to one of inventory "de-load," said Carey. Given his sales estimate revisions, he has lowered his price target on Aurora Cannabis (ACB) shares to $5 from $6, cut his Canopy Growth (CGC) price target to $23 from $27, trimmed his Cronos Group (CRON) target to $13 from $16 and decreased his Hexo (HEXO) target to $2 from $2.50. Carey keeps a Buy rating on Cronos, has Neutral ratings on Aurora and Canopy and maintains an Underperform rating on Hexo.